Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know

Analysts have been steadily raising their estimates for Chemomab Therapeutics. Over the past three months, the Zacks Consensus Estimate for the company has increased 33.3%. The upgrade of Chemomab Therapeutics to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging ...